Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1960 1
1963 1
1964 3
1965 1
1966 2
1967 5
1968 3
1969 4
1970 1
1973 2
1974 4
1975 4
1976 3
1977 2
1978 7
1979 4
1980 12
1981 5
1982 4
1983 8
1984 3
1985 3
1986 7
1987 4
1988 8
1989 6
1990 9
1991 1
1992 7
1993 9
1994 5
1995 4
1996 3
1997 3
1998 19
1999 11
2000 6
2001 11
2002 10
2003 10
2004 6
2005 16
2006 12
2007 17
2008 15
2009 23
2010 32
2011 20
2012 30
2013 36
2014 39
2015 26
2016 40
2017 48
2018 54
2019 48
2020 61
2021 54
2022 59
2023 61
2024 66
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

874 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H; IMpower010 Investigators. Felip E, et al. Among authors: sugawara s. Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20. Lancet. 2021. PMID: 34555333 Clinical Trial.
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Planchard D, et al. Among authors: sugawara s. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. N Engl J Med. 2023. PMID: 37937763 Clinical Trial.
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, Rodríguez-Cid J, Tafreshi A, Cheng Y, Lee KH, Golf A, Sugawara S, Robinson AG, Halmos B, Jensen E, Schwarzenberger P, Pietanza MC, Paz-Ares L. Novello S, et al. Among authors: sugawara s. J Clin Oncol. 2023 Apr 10;41(11):1999-2006. doi: 10.1200/JCO.22.01990. Epub 2023 Feb 3. J Clin Oncol. 2023. PMID: 36735893 Free PMC article. Clinical Trial.
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J. Shankar B, et al. Among authors: sugawara s. JAMA Oncol. 2020 Dec 1;6(12):1952-1956. doi: 10.1001/jamaoncol.2020.5012. JAMA Oncol. 2020. PMID: 33119034 Free PMC article.
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I. Shiraishi Y, et al. Among authors: sugawara s. JAMA Oncol. 2024 Mar 1;10(3):315-324. doi: 10.1001/jamaoncol.2023.5258. JAMA Oncol. 2024. PMID: 38127362 Free PMC article. Clinical Trial.
Antigen-specific memory NK cell responses against HIV and influenza use the NKG2/HLA-E axis.
Jost S, Lucar O, Lee E, Yoder T, Kroll K, Sugawara S, Smith S, Jones R, Tweet G, Werner A, Tomezsko PJ, Dugan HL, Ghofrani J, Rascle P, Altfeld M, Müller-Trutwin M, Goepfert P, Reeves RK. Jost S, et al. Among authors: sugawara s. Sci Immunol. 2023 Dec 8;8(90):eadi3974. doi: 10.1126/sciimmunol.adi3974. Epub 2023 Dec 8. Sci Immunol. 2023. PMID: 38064568 Free PMC article.
Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
Mitsudomi T, Ito H, Okada M, Sugawara S, Shio Y, Tomii K, Okami J, Sakakura N, Kubota K, Takamochi K, Atagi S, Tsuboi M, Oizumi S, Ikeda N, Ohde Y, Ntambwe I, Mahmood J, Cai J, Tanaka F. Mitsudomi T, et al. Among authors: sugawara s. Cancer Sci. 2024 Feb;115(2):540-554. doi: 10.1111/cas.16030. Epub 2023 Dec 14. Cancer Sci. 2024. PMID: 38098261 Free PMC article. Clinical Trial.
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, Sugawara S, Shiraishi Y, Teraoka S, Azuma K, Daga H, Yamaguchi M, Kodaira T, Satouchi M, Shimokawa M, Yamamoto N, Nakagawa K; West Japan Oncology Group (WJOG). Tachihara M, et al. Among authors: sugawara s. JAMA Oncol. 2023 Nov 1;9(11):1505-1513. doi: 10.1001/jamaoncol.2023.3309. JAMA Oncol. 2023. PMID: 37676681 Free PMC article. Clinical Trial.
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.
Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I. Shiraishi Y, et al. Among authors: sugawara s. Lancet Respir Med. 2024 Nov;12(11):877-887. doi: 10.1016/S2213-2600(24)00185-1. Epub 2024 Aug 16. Lancet Respir Med. 2024. PMID: 39159638 Clinical Trial.
874 results